CD19 and mantle cell lymphoma: New ADC in MCL including antibodies targeting novel antigens such as receptor tyrosine kinase‐like orphan receptor 1 (ROR1) and novel payloads for already known targets, such as CD19‐targeted therapy, are under assessment in clinical trials (ClinicalTrials.gov: NCT02669017, NCT02669017 and NCT03424603).